Alpha Centric Advisors LLC Mirati Therapeutics, Inc. Transaction History

Alpha Centric Advisors LLC

  • $118 Million
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 07, 2023
BUY
$41.27 - $98.62 $577,780 - $1.38 Million
14,000 New
14,000 $634,000
Q4 2020

Mar 11, 2022
SELL
$162.05 - $240.27 $12,964 - $19,221
-80 Closed
0 $0
Q3 2020

Mar 11, 2022
SELL
$113.26 - $167.27 $13,591 - $20,072
-120 Reduced 60.0%
80 $13,000
Q2 2020

Mar 11, 2022
BUY
$72.01 - $120.39 $14,402 - $24,078
200 New
200 $23,000

Others Institutions Holding MRTX

# of Institutions
16
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email